Beta-thalassemia is a heritable blood disorder characterized by deficiency (beta+) or complete absence (beta0) of synthesis of the beta globin chains of hemoglobin, as described in the certified knowledge packet. According to GeneReviews-sourced data, beta-thalassemia has two clinically significant forms: beta-thalassemia major, associated with absent or severely reduced beta globin production requiring regular red blood cell transfusions to sustain survival, and beta-thalassemia intermedia, associated with milder reduction that permits greater residual hemoglobin production and a more variable clinical course. The resulting imbalance between alpha and non-alpha globin chains leads to ineffective erythropoiesis, progressive anemia, and the characteristic multi-organ complications of undertreated disease. GeneReviews-sourced prevalence data note that beta-thalassemia is more prevalent in populations from the Mediterranean, the Middle East, Central and Southeast Asia, and the Indian subcontinent, with the highest reported incidences in Cyprus (14%), Sardinia (12%), and Southeast Asia — a distribution closely paralleling that of endemic Plasmodium falciparum malaria, reflecting historical selective pressure. Three certified subtypes are documented in the knowledge packet: a silent allele form, a specific genomic variant form, and dominant beta-thalassemia.

Clinical manifestations of beta-thalassemia vary by form. According to GeneReviews-sourced data, individuals with beta-thalassemia major typically come to medical attention within the first two years of life. Early features include progressive pallor, poor weight gain, stunted growth, mild jaundice, and hepatosplenomegaly. Laboratory findings at presentation include severe microcytic hypochromic anemia with anisopoikilocytosis and nucleated red blood cells on peripheral blood smear, reduced or absent hemoglobin A on hemoglobin analysis, and increased hemoglobin A2 with or without increased hemoglobin F. Without regular red blood cell transfusion, affected individuals cannot maintain hemoglobin levels adequate for survival. Beta-thalassemia intermedia has a more variable presentation: affected individuals have milder anemia that does not require regular transfusions from early childhood, and the age of presentation is correspondingly more variable. Per GeneReviews-sourced data, long-term complications in transfusion-dependent individuals include iron accumulation in the liver, endocrine glands, and heart over time, contributing to organ-specific morbidity. GeneReviews genotype-phenotype data note that the clinical severity of beta-thalassemia depends on the extent of alpha/non-alpha globin chain imbalance; unassembled alpha globin chains that precipitate as inclusions damage erythroid precursors in the bone marrow and spleen, causing ineffective erythropoiesis.

Beta-thalassemia results from deficiency or complete absence of beta globin chain synthesis, as described in the certified knowledge packet. According to GeneReviews-sourced genetic counseling data, beta-thalassemia major and beta-thalassemia intermedia are inherited in an autosomal recessive manner. The certified packet does not list specific gene symbols in the structured known-genes field; the characterization of the molecular basis is drawn from the GeneReviews-sourced clinical data, which describes beta0 variants (absent hemoglobin subunit beta production) and beta+ variants (reduced production). Biallelic beta0 variants typically result in beta-thalassemia major; beta+ variants and compound heterozygous combinations result in milder forms including beta-thalassemia intermedia. The dominant beta-thalassemia subtype — documented in the certified packet as one of three listed subtypes — follows a distinct inheritance pattern as a heterozygous condition.

Diagnosis of beta-thalassemia major, per GeneReviews-sourced data, is suggested in infants or children under two years of age with pallor, poor weight gain, stunted growth, mild jaundice, and hepatosplenomegaly. Laboratory evaluation includes hemoglobin electrophoresis, isoelectric focusing, or high-performance liquid chromatography (HPLC) on newborn blood spots showing reduced or absent hemoglobin A, increased hemoglobin A2 with or without increased hemoglobin F, absence of iron deficiency, and severe microcytic hypochromic anemia. Molecular analysis to determine globin genotype is included in the initial evaluation framework documented in the GeneReviews management data. Newborn screening programs incorporating hemoglobin electrophoresis can identify affected infants prior to symptom onset. Beta-thalassemia intermedia may present later and with less severe findings, requiring analogous hematologic investigation. GeneReviews-sourced surveillance data describe ongoing assessments for individuals with beta-thalassemia major including complete blood counts, physical examination by a physician familiar with the disease manifestations, and growth and development assessments throughout childhood.

No approved treatments are listed in the structured approved-treatments field of the certified knowledge packet for beta-thalassemia. Five orphan drug entries are present in the packet, all carrying DESIGNATED or WITHDRAWN status — none represent currently active approved treatments. Withdrawn entries include arginine butyrate, an autologous CRISPR/Cas12a-edited hematopoietic cell product, and sotatercept; designated-status entries include isobutyramide and 2-dimethylbutyrate. Per GeneReviews-sourced management data, comprehensive management of beta-thalassemia major and intermedia has been addressed by the Thalassemia International Federation. The GeneReviews management framework describes hematologic evaluation including hemoglobin electrophoresis and molecular genotyping as part of initial workup. Regular red blood cell transfusions are described in GeneReviews as necessary for survival in beta-thalassemia major, with associated iron chelation and multi-system surveillance. Ongoing clinical research includes gene therapy approaches — the certified trial portfolio includes gene therapy intervention types — as well as erythroid biology modifiers and hemoglobin F induction strategies. GeneReviews-sourced therapies data note investigation of minihepcidin and TMPRSS6 inhibitors targeting iron dysregulation, and pyruvate kinase activators including etavopivat in planned Phase 3 evaluation.

Prognosis for beta-thalassemia depends on disease form, transfusion access, iron chelation management, and individual response to supportive care. The certified packet does not include a structured natural history or prognosis field. GeneReviews-sourced data document that individuals with beta-thalassemia major require regular red blood cell transfusions to survive, and that iron accumulation from long-term transfusions contributes to progressive multi-organ complications over time. The GeneReviews surveillance framework for beta-thalassemia major describes monthly physical examinations and complete blood counts every three to four weeks during illness, reflecting the intensity of longitudinal assessment required for this form. Beta-thalassemia intermedia permits a more variable disease course with later and milder presentation. Prognosis for any individual is shaped by the specific genotype, the degree of globin chain imbalance, access to specialized hematologic care, and emerging therapeutic options in the active research landscape.

Research into beta-thalassemia is active and substantial. The certified research landscape digest documents 507 classified publications, with epidemiology and natural history as the dominant research type; the portfolio also includes gene therapy publications, biomarker studies, and trial-linked publications, with 67 case reports and 66 reviews. Active clinical trials in the certified packet include NCT07673302, a recruiting study evaluating hemoglobin F inducers in patients with beta-thalassemia; NCT07721480, a Phase 2 gene therapy trial for transfusion-dependent beta-thalassemia (not yet recruiting); NCT05356195, a Phase 3 evaluation of CTX001 — a CRISPR-based investigational cell therapy — in pediatric participants with transfusion-dependent thalassemia (active, not recruiting); NCT05904093, a Phase 1 safety and tolerability study of fostamatinib (recruiting); NCT05736419, a Phase 2 study of immune suppression treatment for individuals with sickle cell disease or beta-thalassemia (recruiting); NCT03937817, a biospecimen collection study for globin variant research (recruiting); NCT06931912, a growth evaluation and clinical management study in children and adolescents (active, not recruiting); and NCT07660224, a study examining motivational interviewing for treatment adherence and self-efficacy (not yet recruiting). Sponsor organizations in the certified trial data include Bristol-Myers Squibb, CorrectSequence Therapeutics, and Editas Medicine. The GeneReviews-sourced therapies section additionally references investigation of ST-400, a zinc finger nuclease targeting a globin enhancer, noting that initial results showed limited durability.